Levosimendan in septic cardiac failure (scientific article published on 3 December 2004)

cites work (P2860)

Q33770902	An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.
Q36187050	An emerging role for calcium sensitisation in the treatment of heart failure
Q34605888	Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.
Q35561197	Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study
Q79687121	Levosimendan in septic shock: another piece in the puzzle, but many pieces are still lacking
Q36070389	Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study
Q35761448	Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?
Q37260357	Recent advances in sepsis and septic shock
Q35687065	Sepsis-induced cardiomyopathy
Q79387615	[Role of Levosimendan in intensive care treatment of myocardial insufficiency]

P2093	author name string	M Giacomini
		A Noto
		G Iapichino
		L Stabile
		A Palandi
		C Reali-Forster
P2860	cites work	Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.	Q43793616
		The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts	Q44524574
		Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock	Q64126988
P433	issue	1
P921	main subject	sepsis	Q183134
P304	page(s)	164-165
P577	publication date	2004-12-03
P1433	published in	Intensive Care Medicine	Q15749164
P1476	title	Levosimendan in septic cardiac failure
P478	volume	31

Levosimendan in septic cardiac failure